# US 2026/0083855 A1 · Immunoconjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083855 A1
- Document ID: US20260083855A1
- Status: Published application
- Kind: A1
- Application number: 19/267,102
- Filed: 2025-07-11
- Published: 2026-03-26
- Earliest claimed: 2023-01-20
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Laura CODARRI DEAK; Anne FREIMOSER-GRUNDSCHOBER; Ralf Joerg HOSSE; Christian KLEIN; Ekkehard MOESSNER; Valeria GONZALEZ NICOLINI; Pablo UMAÑA FERNÁNDEZ; Inja WALDHAUER
- Web page: https://patentgrep.com/patent/US20260083855A1

## CPC

- A61K 38/2013: {IL-2}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4217: {Receptors for interleukins [IL]}
- A61K 40/4234: {Interleukins [IL]}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/55: IL-2
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/42: against immunoglobulins
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/11: Antigen recognition domain
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/515: CD3, T-cell receptor complex
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

## Claims

### Claim 1

An immunoconjugate comprising a mutant IL-2 polypeptide and an antibody that binds to PD-1, wherein the mutant IL-2 polypeptide is a human IL-2 molecule comprising the amino acid substitutions F42A, Y45A, L72G and Q126T (numbering relative to the human IL-2 sequence SEQ ID NO: 90).

### Claim 2 (depends on 1)

The immunoconjugate of claim 1, wherein the antibody comprises
(a) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:74, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:75, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:76, and
(b) a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:77, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:78, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:79.

### Claim 3 (depends on 1)

The immunoconjugate of claim 1,
wherein the antibody comprises (a) a heavy chain variable region (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:80, and (b) a light chain variable region (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:81.

### Claim 4 (depends on 1)

The immunoconjugate of claim 1, wherein the mutant IL-2 polypeptide further comprises the amino acid substitution T3A and/or the amino acid substitution C125A.

### Claim 5 (depends on 1)

The immunoconjugate of claim 1, wherein the mutant IL-2 polypeptide comprises the sequence of SEQ ID NO: 92.

### Claim 6 (depends on 1)

The immunoconjugate of claim 1, wherein the immunoconjugate comprises not more than one mutant IL-2 polypeptide.

### Claim 7 (depends on 1)

The immunoconjugate of claim 1, wherein the antibody comprises an Fc domain composed of a first and a second subunit.

### Claim 8 (depends on 7)

The immunoconjugate of claim 7, wherein the Fc domain is an IgG1 subclass Fc domain.

### Claim 9 (depends on 6)

The immunoconjugate of claim 6, wherein the Fc domain is a human Fc domain.

### Claim 10

(canceled)

### Claim 11 (depends on 7)

The immunoconjugate of claim 7, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.

### Claim 12 (depends on 7)

The immunoconjugate of claim 7, wherein in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.

### Claim 13 (depends on 7)

The immunoconjugate of claim 7, wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V) and optionally the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A), each as numbered according to Kabat EU index.

### Claim 14 (depends on 13)

The immunoconjugate of claim 13, wherein in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C) or the glutamic acid residue at position 356 is replaced with a cysteine residue (E356C), and in the second subunit of the Fc domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C), each as numbered according to Kabat EU index.

### Claim 15 (depends on 7)

The immunoconjugate of claim 7, wherein the mutant IL-2 polypeptide is fused at its amino-terminal amino acid to the carboxy-terminal amino acid of one of the subunits of the Fc domain, particularly the first subunit of the Fc domain, optionally through a linker peptide.

### Claim 16

(canceled)

### Claim 17 (depends on 7)

The immunoconjugate of claim 7, wherein the Fc domain comprises one or more amino acid substitutions that reduces binding to an Feγ receptor, and/or antibody-dependent cell-mediated cytotoxicity (ADCC).

### Claim 18 (depends on 17)

The immunoconjugate of claim 17, wherein said one or more amino acid substitution is at one or more position selected from the group of L234, L235, and P329, as numbered according to Kabat EU index.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The immunoconjugate of claim 1, comprising a polypeptide comprising an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:21, a polypeptide comprising an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:22, and a polypeptide comprising an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:35.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

One or more isolated polynucleotide encoding the immunoconjugate of claim 1.

### Claim 23 (depends on 22)

One or more vector, particularly expression vector, comprising the polynucleotide(s) of claim 22.

### Claim 24 (depends on 22)

A host cell comprising the polynucleotide(s) of claim 22.

### Claim 25 (depends on 24)

A method of producing an immunoconjugate comprising a mutant IL-2 polypeptide and an antibody that binds to PD-1, comprising (a) culturing the host cell of claim 24 under conditions suitable for the expression of the immunoconjugate, and optionally (b) recovering the immunoconjugate.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A pharmaceutical composition comprising the immunoconjugate of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 28

-32. (canceled)

### Claim 33 (depends on 1)

A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the immunoconjugate of claim 1 in a pharmaceutically acceptable form.

### Claim 34 (depends on 33)

The method of claim 33, wherein said disease is cancer.

### Claim 35 (depends on 1)

A method of stimulating the immune system of an individual, comprising administering to said individual an effective amount of a composition comprising the immunoconjugate of claim 1 in a pharmaceutically acceptable form.

### Claim 36

(canceled)
